POTUS Is Receiving Monoclonal Antibodies

Development of Regeneron mAbs was extremely promising. FDA double blind study structure made test pt acquisition difficult for study. I am glad they moved the mAb direction.

POTUS is fatigued with low-grade temp.

quote:

---

Regeneron’s Covid-19 antibody may help non-hospitalized patients recover faster, early data show
By Matthew Herper
Sept 29, 2020

New data from the biotechnology firm Regeneron seem likely to add to the excitement about drugs called monoclonal antibodies as treatments for Covid-19, but experts caution more data will be needed to know how potentially beneficial the medicines are.

A high dose of the company’s antibody cocktail, REGN-COV2, led levels of the virus to decrease more quickly in infected, non-hospitalized patients, potentially indicating the treatment may help them get better, Regeneron reported Tuesday via press release. Full results will be published at a later date.

“There’s nothing bad about these results, you just can’t say much about how transformative this is going to be,” said Eric Topol, director of the Scripps Research Translational Institute. As with data from a similar antibody, developed by Eli Lilly, he warned that the data so far should not be enough for the Food and Drug Administration to grant an emergency use authorization.

LINK

---